Literature DB >> 1562258

Reoperation following diabetic vitrectomy.

G C Brown1, W S Tasman, W E Benson, J A McNamara, R C Eagle.   

Abstract

A review of 484 consecutive eyes that were undergoing an initial pars plana vitrectomy for the sequelae of proliferative diabetic retinopathy disclosed that 41 eyes (8.5%) required one or more additional vitrectomy operations. The primary causes for reoperation included rhegmatogenous retinal detachment in 18 (44%) of the 41 eyes, recurrent vitreous hemorrhage in 21 eyes (51%), and glaucoma in two eyes (5%). The visual prognosis was worse in the group with rhegmatogenous retinal detachment, with 10 (56%) of 18 eyes progressing to no light perception (P = .003). Severe preretinal and subretinal fibrous proliferation, as demonstrated histopathologically, accounted in large part for the poor result. The preretinal membrane formation appeared to occur secondary to a combination of diabetic extraretinal vascular growth and proliferative vitreoretinopathy. Among the total group of 41 eyes that required subsequent surgery, the retina eventually remained detached in 18 eyes (44%), and phthisis bulbi occurred in 13 eyes (32%). Rubeosis iridis developed in 17 (94%) of 18 eyes in which the retina remained detached.

Entities:  

Mesh:

Year:  1992        PMID: 1562258     DOI: 10.1001/archopht.1992.01080160084037

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  13 in total

1.  Fibrovascular ingrowth and recurrent haemorrhage following diabetic vitrectomy.

Authors:  J F West; Z J Gregor
Journal:  Br J Ophthalmol       Date:  2000-08       Impact factor: 4.638

2.  Cryotherapy of sclerotomy sites for prevention of late post-vitrectomy diabetic hemorrhage: a randomized clinical trial.

Authors:  Morteza Entezari; Alireza Ramezani; Hamid Ahmadieh; Pejman Bakhtiari; Mehdi Yaseri; Kian Soltani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-09-25       Impact factor: 3.117

3.  Long-term results of vitreous surgery for proliferative diabetic retinopathy.

Authors:  P Sima; T Zoran
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

4.  Intravitreal ranibizumab versus vitrectomy for recurrent vitreous haemorrhage after pars plana vitrectomy for proliferative diabetic retinopathy: a prospective study.

Authors:  Irini Chatziralli; Eleni Dimitriou; George Theodossiadis; Evgenia Bourouki; Eleni Bagli; George Kitsos; Panagiotis Theodossiadis
Journal:  Int Ophthalmol       Date:  2019-12-02       Impact factor: 2.031

5.  Postvitrectomy diabetic vitreous hemorrhage in proliferative diabetic retinopathy.

Authors:  Lei Shi; Yi-Fei Huang
Journal:  J Res Med Sci       Date:  2012-09       Impact factor: 1.852

6.  Twenty-seven-gauge vitrectomy for combined tractional and rhegmatogenous retinal detachment involving the macula associated with proliferative diabetic retinopathy.

Authors:  Yousef J Cruz-Iñigo; María H Berrocal
Journal:  Int J Retina Vitreous       Date:  2017-10-09

7.  Pars Plana Vitrectomy Reoperations for Complications of Proliferative Diabetic Retinopathy.

Authors:  Hasenin Al-Khersan; Michael J Venincasa; Amy Kloosterboer; Jayanth Sridhar; William E Smiddy; Justin H Townsend; Harry W Flynn
Journal:  Clin Ophthalmol       Date:  2020-06-10

Review 8.  Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.

Authors:  Jonathan M Smith; David H W Steel
Journal:  Cochrane Database Syst Rev       Date:  2015-08-07

9.  Intravitreal Ranibizumab Injection as an Adjuvant in the Treatment of Neovascular Glaucoma Accompanied by Vitreous Hemorrhage after Diabetic Vitrectomy.

Authors:  Xi Shen; Yanwei Chen; Yanuo Wang; Lu Yang; Yisheng Zhong
Journal:  J Ophthalmol       Date:  2016-05-16       Impact factor: 1.909

10.  Vitreous rebleed following sutureless vitrectomy: Incidence and risk factors.

Authors:  Prabhushanker Mahalingam; Tasneem Tameem Topiwalla; Geetha Ganesan
Journal:  Indian J Ophthalmol       Date:  2018-04       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.